• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks
    life science investing

    Biotech Sector in for Third Decade of Gains: Credit Suisse

    Charlotte McLeod
    Jan. 09, 2015 09:47AM PST
    Life Science Investing News

    The Financialist reported that the biotech sector may be in for a third decade of gains, at least according to Credit Suisse Group AG (NYSE:CS).

    The Financialist reported that the biotech sector may be in for a third decade of gains, at least according to Credit Suisse Group AG (NYSE:CS).

    As quoted in the market news:

    The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit wonders to mature companies with multiple blockbuster products. And now the third is just starting to emerge – Credit Suisse calls it Biotech 3.0 – that looks likely to continue to 2020 and beyond.

    For the past four years, biotech stocks have been the top-performing industry in the S&P 500, and the recent outperformance has been notable: a 74 percent gain in 2013 (versus 30 percent for the S&P 500) and a 42 percent gain in 2014 (versus 11 percent). And Credit Suisse Head of Global Biotechnology Research Ravi Mehrotra expects the stocks to beat the market once again this year. ‘This multi-year outperformance has not been a simple sentiment-driven bull run, but rather a fundamental rerating of the biotech sector,’ he writes in a recent report.

    Click here to read the full report from The Financialist.

    credit suisselife science investingnyse:cs
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Numinus Wellness Announces Change of Auditor

    Repayment of Lind Facility with Successful Capital Raise

    Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

    Trading Halt

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing News Stocks

    Defence Therapeutics Class A

    DTC:CC

    Cloud DX

    CDX:CA

    BioHarvest Sciences

    BHSC:CNX

    Billy Goat Brands

    GOAT:CC

    Contakt World

    HELP:CNX
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES